Digital Contract

@csrf

Back

Understanding current perceptions, newer therapies and future directions in Diabetes Management : (New- DM Survey)

Doctor’s details

@if(isset(session()->get('doctor')['vCentralCode']))

Doctor Name *

@else

Doctor Name *

@endif

Age *

Gender *

Male Female

Doctor’s Degree *

Specialty *

Predominant type of practice *

Multi-specialty hospital

Clinic/ nursing home

Government hospital/ medical college

Mixed

City *

Survey Questionnaire Form

According to you, which are the top 3 important aspects of the Ominous Octet that are more prevalent in Indian diabetes patients? (more than one option can be selected) *

Beta cell dysfunction – impaired insulin secretion

Alpha cell dysfunction – impaired glucagon secretion

Increased hepatic glucose output

Impaired incretin effect

Insulin resistance

Decreased glucose uptake by skeletal muscles

Increased glucose reabsorption from kidneys

Neurotransmitter defects

In patients with diabetes and with co-morbidities what is the HbA1c target you prefer? *

≤7.5%

≤7%

< 8%

Any other

In elderly diabetes patients >65 years of age (or life expectancy less than 10 years) and with co-morbidities what is the HbA1c target you prefer? *

≤7.5%

≤8%

Any other

In your patients with diabetes and established ASCVD in what percentage would you prefer following class of anti-diabetic drugs? (Please provide % in the table below) *

Class of anti-diabetic drugs	% Of Patients
GLP1 RA	%
SGLT2i	%
Combining both GLP1 RA and SGLT2i	%

Will lower cost generic injectable GLP1 RAs have the potential to delay initiation of insulin for management of diabetes? *

Yes

Can’t say

To some extent (drop down for percentage)

Do you think that low cost generic oral GLP1 agents have the potential to shift upward or early usage in diabetes management because of following parameters ? (Multiple options can be selected) *

Advantage of cardiovascular outcomes

Renal outcome benefits

Superior HbA1c control

Overall safety

Hassle free usage

None of the above

Which of the following is more preferred in management of patients with T2DM with cardiorenal comorbidities? *

Only tight glycemic control is the most important key

tight glycemic control with selection of agents specific for cardio-renal protection is the key

In your clinical practice, patients who are not achieving glycemic control on Metformin monotherapy, which class of anti-diabetic drug would you like to initiate next? *

DPP4i

SGLT2i

Sulphonylurea (SU)

Any other

In patients diagnosed with diabetes and on two drug combinations at what HbA1c would you initiate a third anti-diabetic drug agent ? *

> 7.5 %

> 8 %

>8.5 %

>9 %

In diabetes patients with CKD, which class of drug will be preferred by you as a second line treatment? *

DPP4 Inhibitors

SGLT2 Inhibitors

GLP 1 RAs

SUs (Glimepiride or Glipizide)

Any other

If patients of T2DM are on Met+SU and not having glycemic control which drug will be preferred in clinical practice? *

DPP4 inhibitors

SGLT2i

Which of the following parameter is the most important for fixed dose combination of Dapagliflozin plus Sitagliptin for you? *

Targeting multiple pathophysiological actions

Ensuring durable glycemic control with preservation of beta-cell mass

Additional cardio-renal protection

Improving patient adherence and compliance

Approximately what % of T2DM patients are on SGLT2i and DPP4i combination? *

<25%

25-50%

50-75%

>75%

In your clinical practice what percentage of patients diagnosed with diabetic kidney disease are on nonsteroidal mineralocorticoid receptor antagonist (MRA) treatment? *

<10%

10-20%

20-30%

30-50%

Usually at what stage of CKD, would you consider adding nonsteroidal mineralocorticoid receptor antagonist (MRA) in type 2 diabetes patients ? *

Early stages – I and II

Later stages – III and IV

Across stages – I to IV

Across stages – I to IV along with albuminuria

Patients diagnosed with diabetic CKD would you prefer Dapagliflozin and nonsteroidal mineralocorticoid receptor antagonist combination? *

Yes

Can’t say

I will add Dapagliflozin and Finerenone sequentially

In your clinical practice, patients who are on nonsteroidal mineralocorticoid receptor antagonist how many patients get hyperkalemia requiring dosage titration. ? *

<5%

5-10%

10-15%

15-25%

25-45%

In your clinical practice, patients who are on nonsteroidal mineralocorticoid receptor antagonist how many get discontinued due to hyperkalemia ? *

None

<5%

5-10%

10-15%

How many of your patients diagnosed with T2DM are on medical nutrition therapy? *

5-10%

10-25%

25-50%

>50%

In your clinical practice how many overweight and obese diabetic patients are on injectable GLP-1 RA treatment? *

<5%

5-10%

10-20%

20-30%

30-40%

Clinical evidence of GLP1 RA shows meaningful weight reduction benefit so do you think GLP1 RA utilization will increase in next 5 years? *

Yes, increase by 10%

Yes, increase by 20%

Yes, increase by 30%

No, it will not increase

Any other

If the current cost of injectable GLP-1 RAs gets reduced by 50% then how many overweight and obese patients would receive GLP-1 RAs treatment in your clinical practice? *

<10%

10-25%

25-50%

Any other

In weight management, does the diagnosis of diabetes mellitus have an impact on initiating GLP-1 agonists in patients? *

Yes

Sometimes

Can’t say

Which of the following statement of GLP-1 agonists is a barrier for widespread adoption despite evidence of benefits and if the cost gets reduced by 50% ? *

Patients’ reluctance for injection

GI side effects like nausea & vomiting

Underlying risk of pancreatitis

Any other

When managing weight in your overweight and obese patients, which of the following is most preferred option? *

Inj Liraglutide

Inj Dulaglutide

Inj Semaglutide

Oral semaglutide